Parabilis Medicines

Q2 FY2026 EarningsPBLS.US Q2 FY26 results significantly missed top-line and bottom-line expectations as the company transitions into a large-scale clinical-stage entity following its IPO. Revenue of $0.15M was far below the $16.67M consensus, while the GAAP Net Loss of $52.5M contrasted sharply with the $7.5M profit expectation. Despite the earnings miss, a robust cash position of $1.1B following a $770.5M IPO and a strategic collaboration with Regeneron provides a runway into 2030, shifting investor focus toward late-stage clinical milestones for zolucatetide.